<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240828121241&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;utm_medium=rss&amp;fc=20230708114047
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240828121241&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;utm_medium=rss&amp;fc=20230708114047" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Wed, 28 Aug 2024 16:12:43 +0000</lastbuilddate>
<pubDate>Wed, 28 Aug 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Bleeding risk should guide antithrombotic treatment after percutaneous coronary intervention: a Copernican revolution</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39193814/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240828121241&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 28:ehae542. doi: 10.1093/eurheartj/ehae542. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39193814/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240828121241&v=2.18.0.post9+e462414">39193814</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae542>10.1093/eurheartj/ehae542</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39193814</guid>
<pubDate>Wed, 28 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Marco Valgimigli</dc:creator>
<dc:creator>Antonio Landi</dc:creator>
<dc:date>2024-08-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Bleeding risk should guide antithrombotic treatment after percutaneous coronary intervention: a Copernican revolution</dc:title>
<dc:identifier>pmid:39193814</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae542</dc:identifier>
</item>
<item>
<title>Von Willebrand factor in inflammation and heart failure: beyond thromboembolic and bleeding risk</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39193812/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240828121241&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 28:ehae543. doi: 10.1093/eurheartj/ehae543. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39193812/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240828121241&v=2.18.0.post9+e462414">39193812</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae543>10.1093/eurheartj/ehae543</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39193812</guid>
<pubDate>Wed, 28 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Stefano Ministrini</dc:creator>
<dc:creator>Amedeo Tirandi</dc:creator>
<dc:date>2024-08-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Von Willebrand factor in inflammation and heart failure: beyond thromboembolic and bleeding risk</dc:title>
<dc:identifier>pmid:39193812</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae543</dc:identifier>
</item>
<item>
<title>A line attractor encoding a persistent internal state requires neuropeptide signaling</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39191257/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240828121241&amp;v=2.18.0.post9+e462414
      <description>Internal states drive survival behaviors, but their neural implementation is poorly understood. Recently, we identified a line attractor in the ventromedial hypothalamus (VMH) that represents a state of aggressiveness. Line attractors can be implemented by recurrent connectivity or neuromodulatory signaling, but evidence for the latter is scant. Here, we demonstrate that neuropeptidergic signaling is necessary for line attractor dynamics in this system by using cell-type-specific...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Aug 22:S0092-8674(24)00906-1. doi: 10.1016/j.cell.2024.08.015. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Internal states drive survival behaviors, but their neural implementation is poorly understood. Recently, we identified a line attractor in the ventromedial hypothalamus (VMH) that represents a state of aggressiveness. Line attractors can be implemented by recurrent connectivity or neuromodulatory signaling, but evidence for the latter is scant. Here, we demonstrate that neuropeptidergic signaling is necessary for line attractor dynamics in this system by using cell-type-specific CRISPR-Cas9-based gene editing combined with single-cell calcium imaging. Co-disruption of receptors for oxytocin and vasopressin in adult VMH Esr1<sup>+</sup> neurons that control aggression diminished attack, reduced persistent neural activity, and eliminated line attractor dynamics while only slightly reducing overall neural activity and sex- or behavior-specific tuning. These data identify a requisite role for neuropeptidergic signaling in implementing a behaviorally relevant line attractor in mammals. Our approach should facilitate mechanistic studies in neuroscience that bridge different levels of biological function and abstraction.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39191257/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240828121241&v=2.18.0.post9+e462414">39191257</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.08.015>10.1016/j.cell.2024.08.015</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39191257</guid>
<pubDate>Tue, 27 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>George Mountoufaris</dc:creator>
<dc:creator>Aditya Nair</dc:creator>
<dc:creator>Bin Yang</dc:creator>
<dc:creator>Dong-Wook Kim</dc:creator>
<dc:creator>Amit Vinograd</dc:creator>
<dc:creator>Samuel Kim</dc:creator>
<dc:creator>Scott W Linderman</dc:creator>
<dc:creator>David J Anderson</dc:creator>
<dc:date>2024-08-27</dc:date>
<dc:source>Cell</dc:source>
<dc:title>A line attractor encoding a persistent internal state requires neuropeptide signaling</dc:title>
<dc:identifier>pmid:39191257</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.08.015</dc:identifier>
</item>
<item>
<title>Congress wrap-up: ESC Preventive Cardiology 2024 in Athens</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39190608/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240828121241&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 27:ehae329. doi: 10.1093/eurheartj/ehae329. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39190608/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240828121241&v=2.18.0.post9+e462414">39190608</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae329>10.1093/eurheartj/ehae329</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39190608</guid>
<pubDate>Tue, 27 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Nicolle Kränkel</dc:creator>
<dc:creator>Guido Claessen</dc:creator>
<dc:creator>Ana Abreu</dc:creator>
<dc:creator>Michael Papadakis</dc:creator>
<dc:date>2024-08-27</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Congress wrap-up: ESC Preventive Cardiology 2024 in Athens</dc:title>
<dc:identifier>pmid:39190608</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae329</dc:identifier>
</item>
<item>
<title>The revolution will be digital: a wake-up call from Helsinki's Radical Health Festival</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39190480/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240828121241&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 27:ehae473. doi: 10.1093/eurheartj/ehae473. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39190480/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240828121241&v=2.18.0.post9+e462414">39190480</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae473>10.1093/eurheartj/ehae473</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39190480</guid>
<pubDate>Tue, 27 Aug 2024 06:00:00 -0400</pubDate>
<dc:date>2024-08-27</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The revolution will be digital: a wake-up call from Helsinki's Radical Health Festival</dc:title>
<dc:identifier>pmid:39190480</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae473</dc:identifier>
</item>
<item>
<title>European Society of Cardiology: the 2023 Atlas of Cardiovascular Disease Statistics</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39189413/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240828121241&amp;v=2.18.0.post9+e462414
      <description>This report from the European Society of Cardiology (ESC) Atlas Project updates and expands upon the 2021 report in presenting cardiovascular disease (CVD) statistics for the ESC member countries. This paper examines inequalities in cardiovascular healthcare and outcomes in ESC member countries utilizing mortality and risk factor data from the World Health Organization and the Global Burden of Disease study with additional economic data from the World Bank. Cardiovascular healthcare data were...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 27:ehae466. doi: 10.1093/eurheartj/ehae466. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">This report from the European Society of Cardiology (ESC) Atlas Project updates and expands upon the 2021 report in presenting cardiovascular disease (CVD) statistics for the ESC member countries. This paper examines inequalities in cardiovascular healthcare and outcomes in ESC member countries utilizing mortality and risk factor data from the World Health Organization and the Global Burden of Disease study with additional economic data from the World Bank. Cardiovascular healthcare data were collected by questionnaire circulated to the national cardiac societies of ESC member countries. Statistics pertaining to 2022, or latest available year, are presented. New material in this report includes contemporary estimates of the economic burden of CVD and mortality statistics for a range of CVD phenotypes. CVD accounts for 11% of the EU's total healthcare expenditure. It remains the most common cause of death in ESC member countries with over 3 million deaths per year. Proportionately more deaths from CVD occur in middle-income compared with high-income countries in both females (53% vs. 34%) and males (46% vs. 30%). Between 1990 and 2021, median age-standardized mortality rates (ASMRs) for CVD decreased by median >;50% in high-income ESC member countries but in middle-income countries the median decrease was &lt;12%. These inequalities between middle- and high-income ESC member countries likely reflect heterogeneous exposures to a range of environmental, socioeconomic, and clinical risk factors. The 2023 survey suggests that treatment factors may also contribute with middle-income countries reporting lower rates per million of percutaneous coronary intervention (1355 vs. 2330), transcatheter aortic valve implantation (4.0 vs. 153.4) and pacemaker implantation (147.0 vs. 831.9) compared with high-income countries. The ESC Atlas 2023 report shows continuing inequalities in the epidemiology and management of CVD between middle-income and high-income ESC member countries. These inequalities are exemplified by the changes in CVD ASMRs during the last 30 years. In the high-income ESC member countries, ASMRs have been in steep decline during this period but in the middle-income countries declines have been very small. There is now an important need for targeted action to reduce the burden of CVD, particularly in those countries where the burden is greatest.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39189413/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240828121241&v=2.18.0.post9+e462414">39189413</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae466>10.1093/eurheartj/ehae466</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39189413</guid>
<pubDate>Tue, 27 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Adam Timmis</dc:creator>
<dc:creator>Victor Aboyans</dc:creator>
<dc:creator>Panos Vardas</dc:creator>
<dc:creator>Nick Townsend</dc:creator>
<dc:creator>Aleksandra Torbica</dc:creator>
<dc:creator>Maryam Kavousi</dc:creator>
<dc:creator>Giuseppe Boriani</dc:creator>
<dc:creator>Radu Huculeci</dc:creator>
<dc:creator>Denis Kazakiewicz</dc:creator>
<dc:creator>Daniel Scherr</dc:creator>
<dc:creator>Efstratios Karagiannidis</dc:creator>
<dc:creator>Marta Cvijic</dc:creator>
<dc:creator>Agnieszka Kapłon-Cieślicka</dc:creator>
<dc:creator>Barbara Ignatiuk</dc:creator>
<dc:creator>Pekka Raatikainen</dc:creator>
<dc:creator>Delphine De Smedt</dc:creator>
<dc:creator>Angela Wood</dc:creator>
<dc:creator>Dariusz Dudek</dc:creator>
<dc:creator>Eric Van Belle</dc:creator>
<dc:creator>Franz Weidinger</dc:creator>
<dc:creator>ESC National Cardiac Societies</dc:creator>
<dc:date>2024-08-27</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>European Society of Cardiology: the 2023 Atlas of Cardiovascular Disease Statistics</dc:title>
<dc:identifier>pmid:39189413</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae466</dc:identifier>
</item>
<item>
<title>Novel Mouse Model of Late-Stage Coronary Atherosclerosis With Features of Plaque Rupture and Stroke</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39186532/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240828121241&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 27;150(9):706-709. doi: 10.1161/CIRCULATIONAHA.124.070464. Epub 2024 Aug 26.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39186532/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240828121241&v=2.18.0.post9+e462414">39186532</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070464>10.1161/CIRCULATIONAHA.124.070464</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39186532</guid>
<pubDate>Mon, 26 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Constance Delwarde</dc:creator>
<dc:creator>Masanori Aikawa</dc:creator>
<dc:date>2024-08-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Novel Mouse Model of Late-Stage Coronary Atherosclerosis With Features of Plaque Rupture and Stroke</dc:title>
<dc:identifier>pmid:39186532</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070464</dc:identifier>
</item>
<item>
<title>Established and Emerging Nucleic Acid Therapies for Familial Hypercholesterolemia</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39186530/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240828121241&amp;v=2.18.0.post9+e462414
      <description>Familial hypercholesterolemia (FH) is a genetic disease that leads to elevated low-density lipoprotein cholesterol levels and risk of coronary heart disease. Current therapeutic options for FH remain relatively limited and only partially effective in both lowering low-density lipoprotein cholesterol and modifying coronary heart disease risk. The unique characteristics of nucleic acid therapies to target the underlying cause of the disease can offer solutions unachievable with conventional...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 27;150(9):724-735. doi: 10.1161/CIRCULATIONAHA.123.067957. Epub 2024 Aug 26.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Familial hypercholesterolemia (FH) is a genetic disease that leads to elevated low-density lipoprotein cholesterol levels and risk of coronary heart disease. Current therapeutic options for FH remain relatively limited and only partially effective in both lowering low-density lipoprotein cholesterol and modifying coronary heart disease risk. The unique characteristics of nucleic acid therapies to target the underlying cause of the disease can offer solutions unachievable with conventional medications. DNA- and RNA-based therapeutics have the potential to transform the care of patients with FH. Recent advances are overcoming obstacles to clinical translation of nucleic acid-based medications, including greater stability of the formulations as well as site-specific delivery, making gene-based therapy for FH an alternative approach for treatment of FH.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39186530/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240828121241&v=2.18.0.post9+e462414">39186530</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11349040/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240828121241&v=2.18.0.post9+e462414">PMC11349040</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067957>10.1161/CIRCULATIONAHA.123.067957</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39186530</guid>
<pubDate>Mon, 26 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Tulsi R Damase</dc:creator>
<dc:creator>Roman Sukhovershin</dc:creator>
<dc:creator>Biana Godin</dc:creator>
<dc:creator>Khurram Nasir</dc:creator>
<dc:creator>John P Cooke</dc:creator>
<dc:date>2024-08-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Established and Emerging Nucleic Acid Therapies for Familial Hypercholesterolemia</dc:title>
<dc:identifier>pmid:39186530</dc:identifier>
<dc:identifier>pmc:PMC11349040</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067957</dc:identifier>
</item>
<item>
<title>BMI1 Inhibition Improves Lesion Burden in Cerebral Cavernous Malformations</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39186529/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240828121241&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 27;150(9):738-741. doi: 10.1161/CIRCULATIONAHA.123.067438. Epub 2024 Aug 26.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39186529/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240828121241&v=2.18.0.post9+e462414">39186529</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067438>10.1161/CIRCULATIONAHA.123.067438</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39186529</guid>
<pubDate>Mon, 26 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Mariaelena Valentino</dc:creator>
<dc:creator>Matteo Malinverno</dc:creator>
<dc:creator>Claudio Maderna</dc:creator>
<dc:creator>Van-Cuong Pham</dc:creator>
<dc:creator>Claudia Jasmin Rödel</dc:creator>
<dc:creator>Federica Zanardi</dc:creator>
<dc:creator>Maximiliano Arce</dc:creator>
<dc:creator>Lorenzo Drufuca</dc:creator>
<dc:creator>Grazisa Rossetti</dc:creator>
<dc:creator>Peetra U Magnusson</dc:creator>
<dc:creator>Maria Grazia Lampugnani</dc:creator>
<dc:creator>Elisabetta Dejana</dc:creator>
<dc:creator>Salim Abdelilah-Seyfried</dc:creator>
<dc:creator>Massimiliano Pagani</dc:creator>
<dc:date>2024-08-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>BMI1 Inhibition Improves Lesion Burden in Cerebral Cavernous Malformations</dc:title>
<dc:identifier>pmid:39186529</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067438</dc:identifier>
</item>
<item>
<title>Response by Shridhar et al to Letter Regarding Article, "MDM2 Regulation of HIF Signaling Causes Microvascular Dysfunction in Hypertrophic Cardiomyopathy"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39186528/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240828121241&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 27;150(9):e201-e202. doi: 10.1161/CIRCULATIONAHA.124.069703. Epub 2024 Aug 26.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39186528/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240828121241&v=2.18.0.post9+e462414">39186528</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069703>10.1161/CIRCULATIONAHA.124.069703</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39186528</guid>
<pubDate>Mon, 26 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Puneeth Shridhar</dc:creator>
<dc:creator>Soumojit Pal</dc:creator>
<dc:creator>Nicolas G Clavere</dc:creator>
<dc:creator>Jason R Becker</dc:creator>
<dc:date>2024-08-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Response by Shridhar et al to Letter Regarding Article, "MDM2 Regulation of HIF Signaling Causes Microvascular Dysfunction in Hypertrophic Cardiomyopathy"</dc:title>
<dc:identifier>pmid:39186528</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069703</dc:identifier>
</item>
<item>
<title>Perspectives on Heart Valve Repair</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39186527/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240828121241&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 27;150(9):661-662. doi: 10.1161/CIRCULATIONAHA.124.070262. Epub 2024 Aug 26.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39186527/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240828121241&v=2.18.0.post9+e462414">39186527</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070262>10.1161/CIRCULATIONAHA.124.070262</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39186527</guid>
<pubDate>Mon, 26 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Tirone E David</dc:creator>
<dc:date>2024-08-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Perspectives on Heart Valve Repair</dc:title>
<dc:identifier>pmid:39186527</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070262</dc:identifier>
</item>
<item>
<title>Letter by Sun and Ren Regarding Article, "MDM2 Regulation of HIF Signaling Causes Microvascular Dysfunction in Hypertrophic Cardiomyopathy"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39186526/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240828121241&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 27;150(9):e200. doi: 10.1161/CIRCULATIONAHA.123.068349. Epub 2024 Aug 26.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39186526/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240828121241&v=2.18.0.post9+e462414">39186526</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.068349>10.1161/CIRCULATIONAHA.123.068349</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39186526</guid>
<pubDate>Mon, 26 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Ying Sun</dc:creator>
<dc:creator>Jian Ren</dc:creator>
<dc:date>2024-08-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Sun and Ren Regarding Article, "MDM2 Regulation of HIF Signaling Causes Microvascular Dysfunction in Hypertrophic Cardiomyopathy"</dc:title>
<dc:identifier>pmid:39186526</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.068349</dc:identifier>
</item>
<item>
<title>Inhalable Stem Cell Exosomes Promote Heart Repair After Myocardial Infarction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39186525/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240828121241&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In both rodent and swine models, our data proved the feasibility, efficacy, and general safety of SCENT treatment against acute MI injury, laying the groundwork for clinical investigation. Moreover, the EC-Cd36^(fl/-) mouse model provides the first in vivo evidence showing that conditional EC-CD36 knockout can ameliorate cardiac injury. Our study introduces a noninvasive treatment option for heart disease and identifies new potential therapeutic targets.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 27;150(9):710-723. doi: 10.1161/CIRCULATIONAHA.123.065005. Epub 2024 Aug 26.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Exosome therapy shows potential for cardiac repair after injury. However, intrinsic challenges such as short half-life and lack of clear targets hinder the clinical feasibility. Here, we report a noninvasive and repeatable method for exosome delivery through inhalation after myocardial infarction (MI), which we called stem cell-derived exosome nebulization therapy (SCENT).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Stem cell-derived exosomes were characterized for size distribution and surface markers. C57BL/6 mice with MI model received exosome inhalation treatment through a nebulizer for 7 consecutive days. Echocardiographies were performed to monitor cardiac function after SCENT, and histological analysis helped with the investigation of myocardial repair. Single-cell RNA sequencing of the whole heart was performed to explore the mechanism of action by SCENT. Last, the feasibility, efficacy, and general safety of SCENT were demonstrated in a swine model of MI, facilitated by 3-dimensional cardiac magnetic resonance imaging.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Recruitment of exosomes to the ischemic heart after SCENT was detected by ex vivo IVIS imaging and fluorescence microscopy. In a mouse model of MI, SCENT ameliorated cardiac repair by improving left ventricular function, reducing fibrotic tissue, and promoting cardiomyocyte proliferation. Mechanistic studies using single-cell RNA sequencing of mouse heart after SCENT revealed a downregulation of <i>Cd36</i> in endothelial cells (ECs). In an EC-<i>Cd36</i><sup>fl/-</sup> conditional knockout mouse model, the inhibition of CD36, a fatty acid transporter in ECs, led to a compensatory increase in glucose utilization in the heart and higher ATP generation, which enhanced cardiac contractility. In pigs, cardiac magnetic resonance imaging showed an enhanced ejection fraction (Δ=11.66±5.12%) and fractional shortening (Δ=5.72±2.29%) at day 28 after MI by SCENT treatment compared with controls, along with reduced infarct size and thickened ventricular wall.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In both rodent and swine models, our data proved the feasibility, efficacy, and general safety of SCENT treatment against acute MI injury, laying the groundwork for clinical investigation. Moreover, the EC-<i>Cd36</i><sup>fl/-</sup> mouse model provides the first in vivo evidence showing that conditional EC-CD36 knockout can ameliorate cardiac injury. Our study introduces a noninvasive treatment option for heart disease and identifies new potential therapeutic targets.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39186525/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240828121241&v=2.18.0.post9+e462414">39186525</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11349039/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240828121241&v=2.18.0.post9+e462414">PMC11349039</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065005>10.1161/CIRCULATIONAHA.123.065005</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39186525</guid>
<pubDate>Mon, 26 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Junlang Li</dc:creator>
<dc:creator>Shenghuan Sun</dc:creator>
<dc:creator>Dashuai Zhu</dc:creator>
<dc:creator>Xuan Mei</dc:creator>
<dc:creator>Yongbo Lyu</dc:creator>
<dc:creator>Ke Huang</dc:creator>
<dc:creator>Yuan Li</dc:creator>
<dc:creator>Shuo Liu</dc:creator>
<dc:creator>Zhenzhen Wang</dc:creator>
<dc:creator>Shiqi Hu</dc:creator>
<dc:creator>Halle J Lutz</dc:creator>
<dc:creator>Kristen D Popowski</dc:creator>
<dc:creator>Phuong-Uyen C Dinh</dc:creator>
<dc:creator>Atul J Butte</dc:creator>
<dc:creator>Ke Cheng</dc:creator>
<dc:date>2024-08-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Inhalable Stem Cell Exosomes Promote Heart Repair After Myocardial Infarction</dc:title>
<dc:identifier>pmid:39186525</dc:identifier>
<dc:identifier>pmc:PMC11349039</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065005</dc:identifier>
</item>
<item>
<title>Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39185895/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240828121241&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients with HFpEF and markers of ID, intravenous FCM improved 6MWTD and was associated with fewer serious adverse events. However, the trial lacked sufficient power to identify or refute effects on symptoms or QoL. The potential benefits of intravenous iron in HFpEF with ID should be investigated further in a larger cohort.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 26:ehae479. doi: 10.1093/eurheartj/ehae479. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Evidence is lacking that correcting iron deficiency (ID) has clinically important benefits for patients with heart failure with preserved ejection fraction (HFpEF).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: FAIR-HFpEF was a multicentre, randomized, double-blind trial designed to compare intravenous ferric carboxymaltose (FCM) with placebo (saline) in 200 patients with symptomatic HFpEF and ID (serum ferritin &lt; 100 ng/mL or ferritin 100-299 ng/mL with transferrin saturation &lt; 20%). The primary endpoint was change in 6-min walking test distance (6MWTD) from baseline to week 24. Secondary endpoints included changes in New York Heart Association class, patient global assessment, and health-related quality of life (QoL).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The trial was stopped because of slow recruitment after 39 patients had been included (median age 80 years, 62% women). The change in 6MWTD from baseline to week 24 was greater for those assigned to FCM compared to placebo [least square mean difference 49 m, 95% confidence interval (CI) 5-93; P = .029]. Changes in secondary endpoints were not significantly different between groups. The total number of adverse events (76 vs. 114) and serious adverse events (5 vs. 19; rate ratio 0.27, 95% CI 0.07-0.96; P = .043) was lower with FCM than placebo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with HFpEF and markers of ID, intravenous FCM improved 6MWTD and was associated with fewer serious adverse events. However, the trial lacked sufficient power to identify or refute effects on symptoms or QoL. The potential benefits of intravenous iron in HFpEF with ID should be investigated further in a larger cohort.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39185895/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240828121241&v=2.18.0.post9+e462414">39185895</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae479>10.1093/eurheartj/ehae479</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39185895</guid>
<pubDate>Mon, 26 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Stephan von Haehling</dc:creator>
<dc:creator>Wolfram Doehner</dc:creator>
<dc:creator>Ruben Evertz</dc:creator>
<dc:creator>Tania Garfias-Veitl</dc:creator>
<dc:creator>Carlotta Derad</dc:creator>
<dc:creator>Monika Diek</dc:creator>
<dc:creator>Mahir Karakas</dc:creator>
<dc:creator>Ralf Birkemeyer</dc:creator>
<dc:creator>Gerasimos Fillippatos</dc:creator>
<dc:creator>Mitja Lainscak</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>Piotr Ponikowski</dc:creator>
<dc:creator>Michael Böhm</dc:creator>
<dc:creator>Tim Friede</dc:creator>
<dc:creator>Stefan D Anker</dc:creator>
<dc:date>2024-08-26</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial</dc:title>
<dc:identifier>pmid:39185895</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae479</dc:identifier>
</item>
<item>
<title>Intravenous iron therapy in heart failure with preserved ejection fraction: how far have we walked?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39185864/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240828121241&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 26:ehae490. doi: 10.1093/eurheartj/ehae490. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39185864/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240828121241&v=2.18.0.post9+e462414">39185864</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae490>10.1093/eurheartj/ehae490</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39185864</guid>
<pubDate>Mon, 26 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Veraprapas Kittipibul</dc:creator>
<dc:creator>Robert J Mentz</dc:creator>
<dc:date>2024-08-26</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Intravenous iron therapy in heart failure with preserved ejection fraction: how far have we walked?</dc:title>
<dc:identifier>pmid:39185864</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae490</dc:identifier>
</item>
<item>
<title>Sex-related differences in the clinical course of aortic root and ascending aortic aneurysms: the DisSEXion Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39185705/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240828121241&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients having entered a diagnostic programme, involvement of aortic segments and age- and segment-related growth patterns differ between women and men with AscAA, particularly at an older age. Unravelling of these intertwined observations will provide a deeper understanding of AscAA progression and outcome in women and men and can be used as an evidence base for patient-tailored clinical guideline development.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 26:ehae525. doi: 10.1093/eurheartj/ehae525. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: To explore male-female differences in aneurysm growth and clinical outcomes in a two-centre retrospective Dutch cohort study of adult patients with ascending aortic aneurysm (AscAA).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Adult patients in whom imaging of an AscAA (root and/or ascending: ≥40 mm) was performed between 2007 and 2022 were included. Aneurysm growth was analysed using repeated measurements at the sinuses of Valsalva (SoV) and tubular ascending aorta. Male-female differences were explored in presentation, aneurysm characteristics, treatment strategy, survival, and clinical outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: One thousand eight hundred and fifty-eight patients were included (31.6% female). Median age at diagnosis was 65.4 years (interquartile range: 53.4-71.7) for females and 59.0 years (interquartile range: 49.3-68.0) for males (P &lt; .001). At diagnosis, females more often had tubular ascending aortic involvement (75.5% vs. 70.2%; P = .030) while males more often had SoV involvement (42.8% vs. 21.6%; P &lt; .001). Maximum absolute aortic diameter, at any location, at diagnosis did not differ between females (45.0 mm) and males (46.5 mm; P = .388). In females, tubular ascending growth was faster (P &lt; .001), whereas in males, SoV growth was faster (P = .005), corrected for covariates. Unadjusted 10-year survival was 72.5% [95% confidence interval (CI) 67.8%-77.6%] for females and 78.3% (95% CI 75.3%-81.3%) for males (P = .010). Twenty-three type A dissections occurred, with an incidence rate of 8.2/1000 patient-years (95% CI 4.4-14.1) in females and 2.4/1000 patient-years (95% CI 1.2-4.5) in males [incidence rate ratio females/males: 3.4 (95% CI 1.5-8.0; P = .004)].</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients having entered a diagnostic programme, involvement of aortic segments and age- and segment-related growth patterns differ between women and men with AscAA, particularly at an older age. Unravelling of these intertwined observations will provide a deeper understanding of AscAA progression and outcome in women and men and can be used as an evidence base for patient-tailored clinical guideline development.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39185705/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240828121241&v=2.18.0.post9+e462414">39185705</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae525>10.1093/eurheartj/ehae525</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39185705</guid>
<pubDate>Mon, 26 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Maximiliaan L Notenboom</dc:creator>
<dc:creator>Adine R de Keijzer</dc:creator>
<dc:creator>Kevin M Veen</dc:creator>
<dc:creator>Arjen Gökalp</dc:creator>
<dc:creator>Ad J J C Bogers</dc:creator>
<dc:creator>Robin H Heijmen</dc:creator>
<dc:creator>Roland R J van Kimmenade</dc:creator>
<dc:creator>Guillaume S C Geuzebroek</dc:creator>
<dc:creator>M Mostafa Mokhles</dc:creator>
<dc:creator>Jos A Bekkers</dc:creator>
<dc:creator>Jolien W Roos-Hesselink</dc:creator>
<dc:creator>Johanna J M Takkenberg</dc:creator>
<dc:date>2024-08-26</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Sex-related differences in the clinical course of aortic root and ascending aortic aneurysms: the DisSEXion Study</dc:title>
<dc:identifier>pmid:39185705</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae525</dc:identifier>
</item>
<item>
<title>Microtubules Sequester Acetylated YAP in the Cytoplasm and Inhibit Heart Regeneration</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39185559/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240828121241&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: After myocardial infarction, decreased sirtuin activity enriches YAP acetylation at K265. The growing TUBA4A network sequesters acetylated YAP within the cytoplasm, which is detrimental to cardiac regeneration.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 26. doi: 10.1161/CIRCULATIONAHA.123.067646. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The Hippo pathway effector YAP (Yes-associated protein) plays an essential role in cardiomyocyte proliferation and heart regeneration. In response to physiological changes, YAP moves in and out of the nucleus. The pathophysiological mechanisms regulating YAP subcellular localization after myocardial infarction remain poorly defined.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We identified YAP acetylation at site K265 by in vitro acetylation followed by mass spectrometry analysis. We used adeno-associated virus to express YAP-containing mutations that either abolished acetylation (YAP-K265R) or mimicked acetylation (YAP-K265Q) and studied how acetylation regulates YAP subcellular localization in mouse hearts. We generated a cell line with YAP-K265R mutation and investigated the protein-protein interactors by YAP immunoprecipitation followed by mass spectrometry, then validated the YAP interaction in neonatal rat ventricular myocytes. We examined colocalization of YAP and TUBA4A (tubulin α 4A) by superresolution imaging. Furthermore, we developed YAP-K265R and <i>αMHC-MerCreMer (MCM); Yap-loxP/K265R</i> mutant mice to examine the pathophysiological role of YAP acetylation in cardiomyocytes during cardiac regeneration.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We found that YAP is acetylated at K265 by CBP (CREB-binding protein)/P300 (E1A-binding protein P300) and is deacetylated by nicotinamide phosphoribosyltransferase/nicotinamide adenine dinucleotide/sirtuins axis in cardiomyocytes. After myocardial infarction, YAP acetylation is increased, which promotes YAP cytoplasmic localization. Compared with controls, mice that were genetically engineered to express a K265R mutation that prevents YAP K256 acetylation showed improved cardiac regenerative ability and increased YAP nuclear localization. Mechanistically, YAP acetylation facilitates its interaction with TUBA4A, a component of the microtubule network that sequesters acetylated YAP in the cytoplasm. After myocardial infarction, the microtubule network increased in cardiomyocytes, resulting in the accumulation of YAP in the cytoplasm.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: After myocardial infarction, decreased sirtuin activity enriches YAP acetylation at K265. The growing TUBA4A network sequesters acetylated YAP within the cytoplasm, which is detrimental to cardiac regeneration.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39185559/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240828121241&v=2.18.0.post9+e462414">39185559</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067646>10.1161/CIRCULATIONAHA.123.067646</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39185559</guid>
<pubDate>Mon, 26 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Shijie Liu</dc:creator>
<dc:creator>Vaibhav Deshmukh</dc:creator>
<dc:creator>Fansen Meng</dc:creator>
<dc:creator>Yidan Wang</dc:creator>
<dc:creator>Yuka Morikawa</dc:creator>
<dc:creator>Jeffery D Steimle</dc:creator>
<dc:creator>Rich Gang Li</dc:creator>
<dc:creator>Jun Wang</dc:creator>
<dc:creator>James F Martin</dc:creator>
<dc:date>2024-08-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Microtubules Sequester Acetylated YAP in the Cytoplasm and Inhibit Heart Regeneration</dc:title>
<dc:identifier>pmid:39185559</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067646</dc:identifier>
</item>
<item>
<title>The Fanconi anemia pathway induces chromothripsis and ecDNA-driven cancer drug resistance</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39181133/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240828121241&amp;v=2.18.0.post9+e462414
      <description>Chromothripsis describes the catastrophic shattering of mis-segregated chromosomes trapped within micronuclei. Although micronuclei accumulate DNA double-strand breaks and replication defects throughout interphase, how chromosomes undergo shattering remains unresolved. Using CRISPR-Cas9 screens, we identify a non-canonical role of the Fanconi anemia (FA) pathway as a driver of chromothripsis. Inactivation of the FA pathway suppresses chromosome shattering during mitosis without impacting...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Aug 20:S0092-8674(24)00892-4. doi: 10.1016/j.cell.2024.08.001. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Chromothripsis describes the catastrophic shattering of mis-segregated chromosomes trapped within micronuclei. Although micronuclei accumulate DNA double-strand breaks and replication defects throughout interphase, how chromosomes undergo shattering remains unresolved. Using CRISPR-Cas9 screens, we identify a non-canonical role of the Fanconi anemia (FA) pathway as a driver of chromothripsis. Inactivation of the FA pathway suppresses chromosome shattering during mitosis without impacting interphase-associated defects within micronuclei. Mono-ubiquitination of FANCI-FANCD2 by the FA core complex promotes its mitotic engagement with under-replicated micronuclear chromosomes. The structure-selective SLX4-XPF-ERCC1 endonuclease subsequently induces large-scale nucleolytic cleavage of persistent DNA replication intermediates, which stimulates POLD3-dependent mitotic DNA synthesis to prime shattered fragments for reassembly in the ensuing cell cycle. Notably, FA-pathway-induced chromothripsis generates complex genomic rearrangements and extrachromosomal DNA that confer acquired resistance to anti-cancer therapies. Our findings demonstrate how pathological activation of a central DNA repair mechanism paradoxically triggers cancer genome evolution through chromothripsis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39181133/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240828121241&v=2.18.0.post9+e462414">39181133</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.08.001>10.1016/j.cell.2024.08.001</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39181133</guid>
<pubDate>Sat, 24 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Justin L Engel</dc:creator>
<dc:creator>Xiao Zhang</dc:creator>
<dc:creator>Mingming Wu</dc:creator>
<dc:creator>Yan Wang</dc:creator>
<dc:creator>Jose Espejo Valle-Inclán</dc:creator>
<dc:creator>Qing Hu</dc:creator>
<dc:creator>Kidist S Woldehawariat</dc:creator>
<dc:creator>Mathijs A Sanders</dc:creator>
<dc:creator>Agata Smogorzewska</dc:creator>
<dc:creator>Jin Chen</dc:creator>
<dc:creator>Isidro Cortés-Ciriano</dc:creator>
<dc:creator>Roger S Lo</dc:creator>
<dc:creator>Peter Ly</dc:creator>
<dc:date>2024-08-24</dc:date>
<dc:source>Cell</dc:source>
<dc:title>The Fanconi anemia pathway induces chromothripsis and ecDNA-driven cancer drug resistance</dc:title>
<dc:identifier>pmid:39181133</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.08.001</dc:identifier>
</item>
<item>
<title>Thyroid hormone remodels cortex to coordinate body-wide metabolism and exploration</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39178853/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240828121241&amp;v=2.18.0.post9+e462414
      <description>Animals adapt to environmental conditions by modifying the function of their internal organs, including the brain. To be adaptive, alterations in behavior must be coordinated with the functional state of organs throughout the body. Here, we find that thyroid hormone-a regulator of metabolism in many peripheral organs-directly activates cell-type-specific transcriptional programs in the frontal cortex of adult male mice. These programs are enriched for axon-guidance genes in glutamatergic...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Aug 19:S0092-8674(24)00835-3. doi: 10.1016/j.cell.2024.07.041. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Animals adapt to environmental conditions by modifying the function of their internal organs, including the brain. To be adaptive, alterations in behavior must be coordinated with the functional state of organs throughout the body. Here, we find that thyroid hormone-a regulator of metabolism in many peripheral organs-directly activates cell-type-specific transcriptional programs in the frontal cortex of adult male mice. These programs are enriched for axon-guidance genes in glutamatergic projection neurons, synaptic regulatory genes in both astrocytes and neurons, and pro-myelination factors in oligodendrocytes, suggesting widespread plasticity of cortical circuits. Indeed, whole-cell electrophysiology revealed that thyroid hormone alters excitatory and inhibitory synaptic transmission, an effect that requires thyroid hormone-induced gene regulatory programs in presynaptic neurons. Furthermore, thyroid hormone action in the frontal cortex regulates innate exploratory behaviors and causally promotes exploratory decision-making. Thus, thyroid hormone acts directly on the cerebral cortex in males to coordinate exploratory behaviors with whole-body metabolic state.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39178853/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240828121241&v=2.18.0.post9+e462414">39178853</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.041>10.1016/j.cell.2024.07.041</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39178853</guid>
<pubDate>Fri, 23 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Daniel R Hochbaum</dc:creator>
<dc:creator>Lauren Hulshof</dc:creator>
<dc:creator>Amanda Urke</dc:creator>
<dc:creator>Wengang Wang</dc:creator>
<dc:creator>Alexandra C Dubinsky</dc:creator>
<dc:creator>Hannah C Farnsworth</dc:creator>
<dc:creator>Richard Hakim</dc:creator>
<dc:creator>Sherry Lin</dc:creator>
<dc:creator>Giona Kleinberg</dc:creator>
<dc:creator>Keiramarie Robertson</dc:creator>
<dc:creator>Canaria Park</dc:creator>
<dc:creator>Alyssa Solberg</dc:creator>
<dc:creator>Yechan Yang</dc:creator>
<dc:creator>Caroline Baynard</dc:creator>
<dc:creator>Naeem M Nadaf</dc:creator>
<dc:creator>Celia C Beron</dc:creator>
<dc:creator>Allison E Girasole</dc:creator>
<dc:creator>Lynne Chantranupong</dc:creator>
<dc:creator>Marissa D Cortopassi</dc:creator>
<dc:creator>Shannon Prouty</dc:creator>
<dc:creator>Ludwig Geistlinger</dc:creator>
<dc:creator>Alexander S Banks</dc:creator>
<dc:creator>Thomas S Scanlan</dc:creator>
<dc:creator>Sandeep Robert Datta</dc:creator>
<dc:creator>Michael E Greenberg</dc:creator>
<dc:creator>Gabriella L Boulting</dc:creator>
<dc:creator>Evan Z Macosko</dc:creator>
<dc:creator>Bernardo L Sabatini</dc:creator>
<dc:date>2024-08-23</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Thyroid hormone remodels cortex to coordinate body-wide metabolism and exploration</dc:title>
<dc:identifier>pmid:39178853</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.041</dc:identifier>
</item>
<item>
<title>Memory B cell fitness and anergy has significant links to cancer lethality</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39178833/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240828121241&amp;v=2.18.0.post9+e462414
      <description>Two recent studies reveal that the extent of fitness or anergy in tumor-associated memory B cells is vital to anti-tumor immune response, cancer patient survival, and response to immune therapy. The impact of these seminal findings demonstrates the untapped potential for using B cells to combat the lethality of cancer.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Aug 22;187(17):4551-4553. doi: 10.1016/j.cell.2024.07.037.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Two recent studies reveal that the extent of fitness or anergy in tumor-associated memory B cells is vital to anti-tumor immune response, cancer patient survival, and response to immune therapy. The impact of these seminal findings demonstrates the untapped potential for using B cells to combat the lethality of cancer.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39178833/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240828121241&v=2.18.0.post9+e462414">39178833</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.037>10.1016/j.cell.2024.07.037</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39178833</guid>
<pubDate>Fri, 23 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Daniel Hollern</dc:creator>
<dc:date>2024-08-23</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Memory B cell fitness and anergy has significant links to cancer lethality</dc:title>
<dc:identifier>pmid:39178833</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.037</dc:identifier>
</item>
<item>
<title>OLAH connects fatty acid metabolism to the severity of respiratory viral disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39178832/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240828121241&amp;v=2.18.0.post9+e462414
      <description>Respiratory virus infections may cause profound respiratory illness, yet the factors that underlie disease severity are not well understood. In this issue of Cell, Jia, Crawford, et al.¹ identify the role of oleoyl-ACP-hydrolase (OLAH) in mediating life-threatening inflammation associated with viral respiratory disease severity.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Aug 22;187(17):4549-4551. doi: 10.1016/j.cell.2024.07.032.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Respiratory virus infections may cause profound respiratory illness, yet the factors that underlie disease severity are not well understood. In this issue of Cell, Jia, Crawford, et al.<sup>1</sup> identify the role of oleoyl-ACP-hydrolase (OLAH) in mediating life-threatening inflammation associated with viral respiratory disease severity.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39178832/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240828121241&v=2.18.0.post9+e462414">39178832</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.032>10.1016/j.cell.2024.07.032</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39178832</guid>
<pubDate>Fri, 23 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Rohan Palanki</dc:creator>
<dc:creator>Hannah Yamagata</dc:creator>
<dc:creator>Michael J Mitchell</dc:creator>
<dc:date>2024-08-23</dc:date>
<dc:source>Cell</dc:source>
<dc:title>OLAH connects fatty acid metabolism to the severity of respiratory viral disease</dc:title>
<dc:identifier>pmid:39178832</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.032</dc:identifier>
</item>





























</channel>
</rss>